NCT07082114View on ClinicalTrials.gov

A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

PHASE3RecruitingINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

July 14, 2025

Primary Completion Date

February 16, 2027

Study Completion Date

May 17, 2027

Conditions
Type 2 Diabetes
Interventions
DRUG

HDM1002 100 mg

HDM1002 tablets, 100 mg once daily, 52 weeks

DRUG

HDM1002 200 mg

HDM1002 tablets, 200 mg once daily, 52 weeks

DRUG

HDM1002 400 mg

HDM1002 tablets, 400 mg once daily, 52 weeks

DRUG

Dapagliflozin (DAPA)

dapagliflozin 10mg will be provided

Trial Locations (1)

414000

RECRUITING

Yueyang People's Hospital, Yueyang

All Listed Sponsors
lead

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

INDUSTRY